Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M328Revenue (TTM) $M0.3Net Margin (%)-31,546.5Altman Z-Score2.8
Enterprise Value $M266EPS (TTM) $-1.4Operating Margin %-31,964.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)-31,545.7Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %-19.5Quick Ratio4.7Cash flow > EarningsY
Price/Sales1,0945-y EBITDA Growth Rate %1.1Current Ratio4.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-62.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-72.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M60.0ROIC % (ttm)-434.9Gross Margin Increase y-yN

Gurus Latest Trades with ARWR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARWRGeorge Soros 2014-06-30 Sold Out -0.01%$9.79 - $18.28
($13.09)
$ 5.47-58%Sold Out0
ARWRGeorge Soros 2014-03-31 Buy 0.01%$9.92 - $26.57
($17.36)
$ 5.47-68%New holding44,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARWR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARWR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myszkowski Kenneth AllenCFO 2015-12-30Sell23,347$6.13-10.77view
Lewis David L.Chief Scientific Officer 2015-01-05Sell15,000$8.01-31.71view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-13.45view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-13.45view
McKenney CharlesDirector 2014-10-01Sell2,500$14.7-62.79view
Lewis David L.Chief Scientific Officer 2014-09-30Sell15,000$15.02-63.58view
GIVEN DOUGLAS BDirector 2014-09-26Sell2,000$15.24-64.11view
GIVEN DOUGLAS BDirector 2014-08-15Sell5,000$13.9-60.65view
Myszkowski Kenneth AllenCFO 2014-08-15Sell40,000$14.02-60.98view
McKenney CharlesDirector 2014-06-09Sell22,000$14.32-61.8view

Quarterly/Annual Reports about ARWR:

News about ARWR:

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARWR) : June 17, 2016 Jun 17 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... Jun 15 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
ARWR: Update on Financials for Fiscal Second Quarter Ended March 31, 2016 May 20 2016
ARROWHEAD PHARMACEUTICALS, INC. Financials May 19 2016
Coverage initiated on Arrowhead by Chardan Capital Markets May 19 2016
ETF’s with exposure to Arrowhead Pharmaceuticals, Inc. : May 18, 2016 May 17 2016
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2016 By the Numbers May 17 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... May 16 2016
Edited Transcript of ARWR earnings conference call or presentation 10-May-16 8:30pm GMT May 11 2016
ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 10 2016
Arrowhead Research reports 2Q loss May 10 2016
Arrowhead Research reports 2Q loss May 10 2016
Arrowhead Reports Fiscal 2016 Second Quarter Results May 10 2016
Arrowhead Reports Fiscal 2016 Second Quarter Results May 10 2016
Q2 2016 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close May 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)